Top Page
Kissei Pharmaceutical Co
(OTC:4547)
Kissei Pharmaceutical Co (4547) vs. iShares MSCI Japan ETF (EWJ)
Kissei Pharmaceutical Co Business Overview & Revenue Model
Kissei Pharmaceutical Co Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.33B | 75.58B | 67.49B | 65.38B | 69.04B |
| Gross Profit | 44.06B | 37.34B | 32.38B | 31.24B | 32.72B |
| EBITDA | 20.25B | 18.72B | 17.81B | 20.26B | 10.65B |
| Net Income | 11.96B | 11.16B | 10.53B | 12.92B | 5.29B |
Balance Sheet | |||||
| Total Assets | 244.06B | 260.93B | 221.20B | 238.09B | 268.86B |
| Cash, Cash Equivalents and Short-Term Investments | 48.65B | 45.93B | 49.60B | 53.15B | 44.45B |
| Total Debt | 1.28B | 1.34B | 1.49B | 1.64B | 1.74B |
| Total Liabilities | 33.93B | 39.80B | 26.39B | 35.91B | 48.91B |
| Stockholders Equity | 209.00B | 220.03B | 193.90B | 201.38B | 219.31B |
Cash Flow | |||||
| Free Cash Flow | 2.01B | -3.51B | -9.23B | -386.00M | -4.03B |
| Operating Cash Flow | 6.52B | -1.68B | -6.68B | 1.53B | -2.54B |
| Investing Cash Flow | 4.95B | 8.69B | 6.00B | 10.78B | -9.33B |
| Financing Cash Flow | -9.32B | -10.01B | -3.42B | -2.76B | -4.00B |
Kissei Pharmaceutical Co Technical Analysis
Kissei Pharmaceutical Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $168.07B | 10.50 | 9.60% | 2.12% | 13.89% | 17.38% | |
72 Outperform | $144.15B | 10.95 | 8.77% | 2.89% | 30.52% | 73.96% | |
71 Outperform | ¥183.81B | 15.56 | 5.93% | 2.04% | 15.40% | 7.73% | |
67 Neutral | €110.25B | 19.06 | 4.88% | 2.48% | 5.31% | 90.37% | |
65 Neutral | $177.83B | 32.90 | 4.52% | 0.95% | 10.91% | 2.93% | |
65 Neutral | ¥197.87B | 20.61 | 1.38% | -3.69% | -18.73% | ||
65 Neutral | ¥342.43B | 8.69 | -3.93% | 2.47% | 11.18% | -19.47% |
Kissei Pharmaceutical Co Corporate Events
Kissei Pharmaceutical Co., Ltd. has entered into a licensing agreement with Viridian Therapeutics to acquire exclusive development and sales rights for veligrotug and VRDN-003 in Japan, both of which are potential treatments for thyroid eye disease (TED). This strategic move aligns with Kissei’s medium-term management plan ‘Beyond 80’, aimed at growth and expanding its research and development pipeline, particularly in the area of rare diseases. The agreement is expected to enhance Kissei’s market positioning in Japan and contribute to the treatment of TED, a condition with significant unmet medical needs.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical Co. has revised its financial forecast for the fiscal year ending March 31, 2026, due to a new technology licensing agreement that increases R&D expenses, impacting operating and ordinary profits. Despite this, the company expects to maintain its profit forecast by recording extraordinary income from the sale of investment securities, aimed at improving capital efficiency and funding growth investments.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical reported a 4.9% increase in net sales for the three months ending June 30, 2025, compared to the same period in the previous year. Despite the rise in sales, the operating profit saw a slight decline of 2.3%. The company forecasts a modest growth in profit attributable to owners for the fiscal year ending March 31, 2026, indicating a stable outlook amidst industry challenges.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical Co., Ltd. has completed the disposal of 16,787 treasury shares as restricted stock for its board members and corporate officers. This strategic move, involving a total value of ¥68,490,960, is part of the company’s efforts to align the interests of its leadership with corporate performance, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical Co., Ltd. has announced the launch of TAVALISSE, a spleen tyrosine kinase inhibitor for treating chronic idiopathic thrombocytopenic purpura (ITP), in South Korea through its partner JW Pharmaceutical Corporation. This launch marks a significant expansion of TAVALISSE, which has already been introduced in the United States, Europe, Canada, and the Middle East, and is expected to strengthen Kissei’s position in the treatment of ITP, an intractable disease, while potentially impacting its financial results for the fiscal year ending March 2026.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical Co., Ltd. has announced the disposal of 16,787 treasury shares as restricted stock to its board members and corporate officers, as part of a new compensation system aimed at enhancing corporate value and aligning interests with shareholders. This move, approved at the company’s annual general meeting, reflects a strategic effort to incentivize key personnel and strengthen the company’s market position through sustainable growth initiatives.
The most recent analyst rating on (JP:4547) stock is a Hold with a Yen3600.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
Kissei Pharmaceutical Co reported a significant financial performance for Fiscal 2024, with net sales reaching ¥88,330 million, marking a 16.9% increase year-over-year, and an operating profit of ¥5,773 million, a 43.7% rise. The growth was driven by increased sales in both domestic and international markets, particularly through the expansion of products like Linzagolix and Fostamatinib. The company also saw a rise in R&D expenses due to new product developments and licensing agreements, indicating a strategic focus on innovation and market expansion.
Kissei Pharmaceutical Co., Ltd. has completed the acquisition of 1,369,200 treasury shares, representing 3.20% of its issued shares, for a total cost of 5,216,652,000 yen. This move is part of a flexible capital policy aimed at improving capital efficiency and enhancing shareholder returns, with the acquired shares set to be canceled by June 27, 2025.
Kissei Pharmaceutical Co., Ltd. reported a significant increase in its financial performance for the fiscal year ended March 31, 2025, with net sales rising by 16.9% and operating profit increasing by 43.7%. The company plans to enhance shareholder value through a treasury share purchase and forecasts continued growth in the upcoming fiscal year.
Kissei Pharmaceutical Co., Ltd. has announced a strategic move to acquire and subsequently cancel a portion of its treasury shares. This decision, approved by the Board of Directors, aims to improve capital efficiency and enhance shareholder returns, reflecting the company’s adaptive capital policy in response to market conditions.
Kissei Pharmaceutical Co., Ltd. announced a revision to its executive compensation system, aiming to align director incentives with the company’s sustainable growth and long-term value creation goals. This revision, subject to shareholder approval, introduces a new compensation structure that includes base salary, performance-linked bonuses, and restricted stock compensation, reflecting a strategic shift to enhance corporate governance and stakeholder value.
Kissei Pharmaceutical Co. announced an increase in its year-end dividend to ¥55 per share, reflecting a ¥10 rise from the previous forecast, resulting in an annual dividend of ¥100 per share. This decision is part of the company’s new mid-term management plan, ‘Beyond 80,’ which emphasizes shareholder returns, including a planned allocation of 57 billion yen for dividends and share buybacks over the next five years.
Kissei Pharmaceutical has announced its new five-year management plan, ‘Beyond 80,’ which aims to build on the successes of its previous plan, PEGASUS. The company exceeded its sales targets in 2024 and plans to continue its growth by expanding its R&D pipeline, launching new products, and increasing its international presence. The ‘Beyond 80’ plan focuses on sustainable growth, environmental management, and achieving significant financial metrics, such as an ROE of over 8% and a 10-year average growth rate of over 5% in sales.